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In the last few decades there has been an extensive focus of re-
search towards the rational modiﬁcation of steroid molecules.
This is due to the fact that such type of compounds are less
toxic, less vulnerable to multi-drug resistance (MDR) and
highly bioavailable because of being capable of penetrating
the cell wall. Recent studies reveal that incorporation of het-
eroatom (N/O/S) enhances the biological activities of steroid
molecules. This is proved by various activities shown by these
systems like antimicrobial, anti-inﬂammatory, hypotensive,
hypocholesterolemic and diuretic activities (Manson et al.,1963; Hirschmann et al., 1963, 1964; Wang et al., 1993; Gupta
et al., 1996). As a result, a number of different heterocyclic sys-
tems have been introduced into the core structure of steroids
with pyrazoles, pyrazolines, isoxazoles, isoxazolines, thiazoles,
thiadiazoles, pyridines, pyrimidines, imidazoles, etc. as the
notable ones. Among these heterocycles, pyrazolines occupy
a unique place in the realm of natural and synthetic organic
chemistry (Jung et al., 2005).
Pyrazoline derivatives are synthetic targets of utmost
importance for the researchers, since such type of compounds
have a wide range of biological and pharmaceutical properties
such as analgesic, antipyretic and antiandrogenic activities
(Jung et al., 2005; Amr et al., 2005). Pyrazolines also possess
antidepressant, anti-inﬂammatory and antirheumatic activities
(Palaska et al., 2001; Bansal et al., 2001). Besides this pyrazo-
lines are also used as potent antidiabetic agents (Villhauer
et al., 2002; Ahn et al., 2004). Recently, pyrazolines were re-
ported as a DP-IV inhibitors and antitumor agents (Amr,
2000; Hammam et al., 2000; 2003).
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et al., 2012) and in continuation of our search for biologically
active steroidal pyrazoline derivatives (Shamsuzzaman et al.,
2009), we have developed an efﬁcient synthetic strategy for
the generation of steroidal N-substituted 2-pyrazoline deriva-
tives. These scaffolds are being subjected to biological screen-
ings like antimicrobial and anticancer activities.2. Experimental protocol
Melting points were determined on a Koﬂer apparatus and are
uncorrected. The IR spectra were recorded on KBr pellets with
Pye Unicam SP3-100 spectrophotometer and values are given
in cm1. 1H and 13C NMR spectra were run in CDCl3 on a
JEOL Eclipse (400 and 100 MHz) instrument with tetrameth-
ylsilane (TMS) as internal standard and values are given in
parts per million (ppm) (d). Mass spectra were recorded on a
JEOL SX 102/DA-6000 mass spectrometer. Thin layer chro-
matography (TLC) plates were coated with silica gel G and ex-
posed to iodine vapours to check the homogeneity as well as
the progress of reaction. Sodium sulphate (anhydrous) was
used as a drying agent.
2.1. General procedure for the syntheses of the steroidal
pyrazoline derivatives (4–6)
To a solution of steroidal a,b-unsaturated ketone 1–3 (1 mmol)
in DMSO (10 ml), 2,4-dinitrophenylhydrazine (1 mmol) and
few drops of acetic acid were added. The reaction mixture
was reﬂuxed for 21–35 h. The progress as well as completion
of reaction was monitored by TLC. After completion, the reac-
tion mixture was cooled to room temperature and left over-
night. The precipitate formed was ﬁltered, washed with water
and taken in ether. The ethereal layer was further washed with
water and dried over anhydrous sodium sulphate. Removal of
solvents gave the crude product which was recrystallized from
methanol to furnish corresponding 20-(200,400-dinitrophenyl)-5a-
cholestano [5,7-c d] pyrazolines 4–6.
2.2. 3b-Acetoxy 20-(200,400-dinitrophenyl)-5a-cholestano [5,7-c
d] pyrazoline (4)
Yield (80%); mp: 180 C; Anal. Calcd for C35H50N4O6: C,
67.50, H, 8.09, N, 9.0. found: C, 67.48, H, 8.11, N, 8.98; IR
(KBr) t cm1: 1734 (OCOCH3), 1365 (N‚O), 1242 (C-O),
1314 (C–N), 1630 (C‚N), 1593, 1464, 3130 (aromatic); 1H
NMR (CDCl3, 400 MHz): d 1.5 (s, 2H, C6H), 4.6 (m, 1H, C3
a-H, W½= 15 Hz, A/B trans) (Bhacca and Williams, 1964),
2.01 (s, 3H, OCOCH3), d 9.09 (s, 1H, C300H), 8.2 (d, 1H,
C5
00H), 7.8 (d, 1H, C600H), 1.12 (s, 3H, C10-CH3), 0.71 (s, 3H,
C13-CH3), 0.92 & 0.85 (other methyl protons).
13C NMR
(CDCl3, 100 MHz): d 170, 156, 136, 130, 127, 126, 124, 123,
116, 72, 54, 50, 49, 49, 46, 45,43, 39, 38, 37, 36, 36, 35, 32,
28, 28, 27, 26, 23, 22, 21, 21, 18,17, 12. ESI MS: m/z 622 [M+].
2.3. 3b-Chloro 20-(200,400-dinitrophenyl)-5a-cholestano [5,7-c d]
pyrazoline (5)
Yield (76%); mp: 170 C; Anal. Calcd for C33H47N4O4Cl: C,
66.15, H, 7.91, N, 9.35. found: C, 66.17, H, 7.88, N, 9.37; IR
(KBr) t cm1: 1365 (N‚O), 743(C-Cl), 1325 (C–N), 1635(C‚N), 1590, 1467, 3129 (aromatic); 1H NMR (CDCl3,
400 MHz): 1.6 (s, 2H, C6H), 3.9 (m, 1H, C3 a-H, W½=
17 Hz, A/B trans) (Bhacca and Williams, 1964), d 9.1 (d, 1H,
aromatic), 8.1 (dd, 1H, aromatic), 7.8 (d, 1H, aromatic), 1.12
(s, 3H,C10-CH3), 0.71 (s, 3H, C13-CH3), 0.92 & 0.85 (other
methyl protons). 13C NMR (CDCl3, 100 MHz): d 158, 137,
130, 129, 128, 127, 123, 116, 59, 54, 50, 49, 43, 42, 39, 39,
39, 38, 36, 35, 32, 28, 28, 27, 26, 23, 22, 22, 21, 20, 18, 18,12.
ESI MS: m/z 600/598 [M+].
2.4. 20-(200,400-Dinitrophenyl)-5a-cholestano [5,7-c d] pyrazoline
(6)
Yield (70%); mp: 185 C; Anal. Calcd for C33H48N4O4: C,
70.18, H, 8.57, N, 9.92. found: C, 70.20, H, 8.55, N, 9.94; IR
(KBr) t cm1: 1360 (N‚O), 1333 (C–N), 1640 (C‚N),
1590, 1460, 3095 (aromatic); 1H NMR (CDCl3, 400 MHz): d
1.7 (s, 2H, C6H), d 9.1 (s, 1H, C300H), 8.3 (d, 1H, C500H), 7.8
(d, 1H, C6
00H), 1.12 (s, 3H,C10-CH3), 0.71 (s, 3H, C13-CH3),
0.92 & 0.85 (other methyl protons). 13C NMR (CDCl3,
100 MHz): d 155, 137, 130, 129, 128, 127, 123, 116, 59, 54,
50, 50, 42, 40, 39, 38, 36, 35, 33, 29, 28, 28, 27, 27, 23, 22,
22, 22, 20, 20, 18, 18, 12. ESI MS: m/z 564 [M+].
2.5. Organism culture and in vitro screening (antibacterial
activity)
The in vitro antimicrobial activities of corresponding 20-(200,400-
dinitrophenyl)-5a-cholestano [5,7-c d] pyrazoline 4–6 were
screened for their antibacterial activity against the bacterial cul-
tures of Corynebacterium xerosis (ATCC-373), Staphylococcus
epidermidis (ATCC-29887) and Escherichia coli (ATCC-8739)
by disc diffusion method (Cruickshank et al., 1975; Collins,
1976). Standard inoculums (1 · 107–2 · 107) c.f.u. ml1 (0.5
McFarland standards) was introduced onto the surface of ster-
ile agar plates and a sterile glass spreader was used for even dis-
tribution of the inoculums. 1 mg of every trial compound was
dissolved in 100 ll DMSO to prepare stock solution and from
stock solutions diverse concentrations 10, 20, 25, 50, and
100 lg/ll of every trial compound were prepared. After that
the compounds of diverse concentrations were poured over disk
plate onto it. The discs measuring 6 mm in diameter were pre-
pared from Whatman No. 1 ﬁlter paper and sterilized by dry
heat at 140 C for 1 h. The sterile discs previously soaked in a
known concentration of the test compounds were placed in
nutrient agar medium. Solvent and growth controls were also
kept. Gentamicin was used as positive control. While the disk
poured in DMSO was used as negative control. The plates were
inverted and incubated for 24 h at 37 C. The susceptibility was
assessed on the basis of diameter of zone of inhibition against
different strains of bacteria. Inhibition zones were measured
and compared with standard drug. The bacterial zones of inhi-
bition values are given in Table 1.
Minimum inhibitory concentrations (MIC) were deter-
mined by broth dilution technique. The nutrient broth which
contained logarithmic serially two fold diluted amount of test
compound and controls, were inoculated with approximately
5 · 105 c.f.u. ml1 of actively dividing bacteria cells. The
cultures were incubated for 24 h at 37 C and the growth
was monitored visually and spectrophotometrically. The low-
est concentration (highest dilution) required to arrest the
growth of bacteria was regarded as minimum inhibitory con-
Table 1 Zones of Inhibition of compounds 4–6, standard
(Gentamicin) and negative control (DMSO) with different
bacterial strains.
Compound Zone of Inhibition (mm)
E. coli C. xerosis S. epidermidis
4 17 ± 0.3 13 ± 0.2 15 ± 0.2
5 16 ± 0.1 14 ± 0.3 15 ± 0.3
6 15 ± 0.4 27 ± 0.3 30 ± 0.2
Gentamicin 24 ± 0.2 27 ± 0.1 28 ± 0.3
DMSO – – –
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are given in Table 3.
2.6. Organism culture and in vitro screening (antifungal
activity)
For assaying antifungal activity, different fungal strains like
Mucor azygosporus (MTCC-414), Claviceps purpurea
(MTCC-1479) and Aspergillus niger (MTCC-281) were taken
and antifungal activity was done by agar diffusion method
(Khan, 1997; Verma et al., 1998). Sabourand agar media was
prepared by dissolving peptone (1 g), D-glucose (4 g) and agar
(2 g) in distilled water (100 ml) and adjusting pH to 5.7. Nor-
mal saline was used to make a suspension of spore of fungal
strain for lawning. A loopful of particular fungal strain was
transferred to 3 ml saline to get a suspension of corresponding
species. 20 ml of agar media was poured into each Petri dish.
Excess of suspension was decanted and the plates were dried
by placing in an incubator at 37 C for 1 h. using an agar
punch, wells were made and each well was labelled. 1 mg of
every trial compound was dissolved in 100 ll DMSO to pre-
pare stock solution and from stock solutions diverse concen-
trations 10, 20, 25, 50, and 100 lg/ll of every trial
compound were prepared. After that the compounds of diverse
concentrations were poured over disk plate onto it. A control
was also prepared in triplicate and maintained at 37 C for 3–
4 days. The antifungal activity of each compound was com-
pared with Ketoconazole as standard drug. Inhibition zones
were measured and compared with the controls. The fungal
zones of inhibition values are given in Table 2. The nutrient
broth which contained logarithmic serially two fold diluted
amount of test compound and controls was inoculated with
approximately 1.6 · 104–6 · 106 c.f.u. ml1. The cultures were
incubated for 48 h at 35 C and the growth was monitored.
The lowest concentration (highest dilution) required to arrestTable 2 Zones of Inhibition of compounds 4–6, standard
(Ketoconazole) and negative control (DMSO) with different
fungal strains.
Compound Zone of Inhibition (mm)
M. azygosporus C. purpurea A. niger
4 07 ± 0.1 15 ± 0.4 16 ± 0.1
5 12 ± 0.3 16 ± 0.1 18 ± 0.3
6 17 ± 0.2 15 ± 0.2 18 ± 0.4
Ketoconazole 25 ± 0.2 24 ± 0.3 23 ± 0.2
DMSO – – –the growth of fungus was regarded as minimum inhibitory
concentration (MIC). The MIC’s and MFC’s of compound
4–6 are given in Table 4.
2.7. In vitro anticancer activity
2.7.1. Cell lines and culture conditions
Human cancer cell lines SW480 (human colon adenocarci-
noma cells), HeLa (human cervical cancer cells), A549 (human
lung carcinoma cells), HepG2 (human hepatic carcinoma
cells), HL-60 (human Leukaemia) were taken for the study.
SW480, A549, HL-60 and HepG2 cells were grown in RPMI
1640 supplemented with 10% foetal bovine serum (FBS),
10U penicillin and 100 lg/ml streptomycin at 37 C with 5%
CO2 in a humidiﬁed atmosphere. HeLa cells were grown in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplanted
with FCS and antibiotics as described above for RPMI 1640.
Fresh medium was given every second day and on the day be-
fore the experiments were done. Cells were passaged at precon-
ﬂuent densities, using a solution containing 0.05% trypsin and
0.5 mM EDTA.
2.7.2. Cell viability assay (MTT)
The anticancer activity in vitro was measured using the MTT
assay. The assay was carried out according to known protocol
(Slater et al., 1963; Mosmann, 1983). Exponentially growing
cells were harvested and plated in 96-well plates at a concentra-
tion of 1 · 104 cells/well. After 24 h incubation at 37 C under
a humidiﬁed 5% CO2 to allow cell attachment, the cells in the
wells were, respectively, treated with target compounds at var-
ious concentrations for 48 h. The concentration of DMSO was
always kept below 1.25%, which was found to be non-toxic to
the cells. A solution of 3-(4,5-dimethylthizao1-2-y1)-2,5-diphe-
nyltetrazolium bromide (MTT), was prepared at 5 mg/ml in
phosphate buffered saline (PBS; 1.5 mM KH2PO4, 6.5 mM
Na2HPO4, 137 mM NaCl, 2.7 mM KCl; pH 7.4). 20 ll of this
solution were added to each well. After incubation for 4 h at
37 C in a humidiﬁed incubator with 5% CO2, the medium/
MTT mixtures were removed, and the formazan crystals
formed by the mitochondrial dehydrogenase activity of vital
cells were dissolved in 100 ll of DMSO per well. The absor-
bance of the wells was read with a microplate reader (Bio-
Rad Instruments) at 570 nm. Effects of the drug cell viability
were calculated using cell treated with DMSO as control.
2.8. Data analysis
Cell survival was calculated using the formula: Survival
(%) = [(absorbance of treated cellsabsorbance of culture
medium)/(absorbance of untreated cellsabsorbance of cul-
ture medium)] · 100 (Woerdenbag et al., 1993; Saxena et al.,
2007). The experiment was done in triplicate and the inhibitory
concentration (IC) values were calculated from a dose response
curve. IC50 is the concentration in ‘lM’ required for 50% inhi-
bition of cell growth as compared to that of untreated control.
IC50 values were determined from the linear portion of the
curve by calculating the concentration of agent that reduced
absorbance in treated cells, compared to control cells, by
50%. Evaluation is based on mean values from three indepen-
dent experiments, each comprising at least six microcultures
per concentration level.
HH
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X H O
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X H
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                 X        X 
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                            H (3)                                                             H (6) 
Scheme 1 Formation of Steroidal pyrazolines 4–6.
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3.1. Chemistry
3b-Acetoxy cholest-5-en-7-one 1, 3b-chloro cholest-5-en-7-one
2 and cholest-5-en-7-one 3 were used as starting materials
which have been synthesized by literature methods (Dauben
and Takemura, 1953). The yield of 20-(200,400-dinitrophenyl)-
5a-cholestano [5,7-c d] pyrazolines 4–6 were in the range of
70–80%. All the three compounds (Scheme 1.) were prepared
by reﬂuxing of compounds 1–3 with 2,4-dinitrophenylhydra-
zine in dimethyl sulfoxide (DMSO). The structures of the com-
pounds were established by means of their IR, 1H NMR, 13C
NMR, MS and analytical data. The selected diagnostic bands
of IR spectra of synthesized products provide useful informa-
tion for determining structures of the pyrazoline derivatives.
The absorption bands at 1630–1640 cm1 (C‚N) and1314–
1333 (C–N) conﬁrmed the formation of pyrazoline ring in all
compounds. The absorption bands at 1593, 1464, 3130 cm1
are attributed to the aromatic ring in the products. TheTable 3 MIC’s and MBC’s of compounds 4–6 on different bacteri
Compound E. coli C
MIC MBC M
4 3.125 1.250 1.
5 3.125 1.250 1.
6 3.125 1.250 0.
Table 4 MIC’s and MFC’s of compounds 4–6 with different funga
Compound M. azygosporus
MIC MFC
4 >5.00 –
5 0.25 2.50
6 3.125 1.20absorption bands at 1337–1511 cm1 show the presence of
NO2 in the compounds.
The formation of steroidal pyrazolines was further con-
ﬁrmed with the 1H NMR spectra. Assignments of the signals
are based on the chemical shift and intensity pattern. The 1H
NMR spectra of the compounds exhibited singlet for two pro-
tons of (C6-H) at d 1.5–1.7. The presence of singlet (C300-H,
aromatic) at d 9.06, doublet (C500-H, aromatic) at d 8.2, doublet
(C6
00-H, aromatic) at d 7.8 ppm conﬁrm the presence of aro-
matic ring in the compound. 13C NMR signals are in good
agreement with proposed structures of synthesized com-
pounds. The compounds exhibited signal at d 155–158 which
shows the presence of C‚N. The signals obtained at d 130,
127, 126, 124, 123,116 conﬁrm the presence of aromatic
carbons.
The distinctive signals were observed in the mass spectra of
compounds 4–6 which followed the similar fragmentation pat-
tern. The molecular ion peaks (M+) for compound 4–6 were
observed at m/z 622, 598/600 and 564, respectively.
The stereochemical assignation of C5-N bond has been
established on the basis of half band width (W1/2) values ofal strains.
. xerosis S.epidermidis
IC MBC MIC MBC
250 2.250 3.125 1.250
250 2.50 1.562 0.625
781 0.312 0.195 0.781
l strains.
C. purpurea A. niger
MIC MFC MIC MFC
3.125 2.50 3.125 1.250
3.155 1.250 1.562 0.625
6.250 2.50 1.562 0.625
Table 5 Showing IC50 values of compound 4–6 with different
cancer cell lines.
Compound IC50 (lmol l
1)
SW480 A549 HepG2 HeLa HL60
4 >50 31.71 26.53 >50 27.63
5 27.62 18.31 23.52 33.61 15.39
6 >50 >50 42.16 38.91 >50
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1H NMR spectra of compounds 4 and 5
which clearly suggested that A/B ring junction is trans (Bhacca
and Williams, 1964) and also on the basis of the fact that dur-
ing the reaction, the attack of N of the reagent should be from
that side (a) which is less hindered, not from that side (b) which
is more hindered due to the presence of C10 methyl group,
hence the C5-N bond should be axial (a) and trans to C10
methyl.
3.2. Pharmacology
3.2.1. Antibacterial activity
The in vitro antibacterial activities of steroidal pyrazolines 4–6
were screened for their antibacterial activity against the bacte-
rial cultures of C. xerosis, S. epidermidis and E. coli by disc dif-
fusion method. Standard inoculums (1 · 107–2 · 107 c.f.u ml1
0.5 McFarland standards) were introduced onto the surface of
sterile agar plates and a sterile glass spreader was used for even
distribution of the inoculums. The susceptibility was assessed
on the basis of diameter of zone of inhibition against different
strains of bacteria. Inhibition zones were measured and com-
pared with standard drug, Gentamicin. The bacterial zones
of inhibition values are given in Table 1.
Minimum inhibitory concentrations (MICs) were deter-
mined by broth dilution technique. The nutrient broth which
contained logarithmic serially two fold diluted amount of test
compound and controls, were inoculated with approximately
5 · 105 c.f.u. ml1 of actively dividing bacterial cells. The cul-
tures were incubated for 24 h at 37 C and the growth was
monitored visually and spectrophotometrically. The lowest
concentration (highest dilution) required to arrest the growth
of bacteria was regarded as minimum inhibitory concentration
(MIC). The minimum inhibitory concentrations of compound
4–6 are given in Table 3. The compound 6 was found to be
more potent than the reference drug, Gentamicin, in case of
S. epidermidis by showing larger zone of inhibition than refer-
ence drug. The compound 6 was also equally potent as the ref-
erence drug, Gentamicin, in case of C. xerosis by showing zone
of inhibition of same diameter as that of reference drug.
3.2.2. Antifungal activity
For assaying antifungal activity, different fungal strains like
M. azygosporus, C. purpurea and A. niger were taken and anti-
fungal activity was done by agar diffusion method. The anti-
fungal activity of each compound was compared with
Ketoconazole as standard drug. Inhibition zones were mea-
sured and compared with the controls. The fungal zones of
inhibition values are given in Table 2. The nutrient broth,
which contained logarithmic serially two fold diluted amount
of test compound and controls was inoculated with approxi-
mately 1.6 · 104–6 · 106 c.f.u. ml1. The cultures were incu-
bated for 48 h at 35 C and the growth was monitored. Thelowest concentration (highest dilution) required to arrest the
growth of fungus was regarded as minimum inhibitory concen-
tration (MIC). The minimum inhibitory concentrations of
compound 4–6 are given in Table 4.
The antifungal screening data showed moderate to good
fungal inhibition. Among the screened compounds, 5 and 6
were found to have good zones of inhibition. The compound
5 and 6 showed moderate to good inhibition against A. niger
strain. The compound 6 also showed moderate inhibition
againstM. azygosporus strain in comparison with the reference
drug, Ketoconazole.
3.2.3. Anticancer activity
The in vitro anticancer screening of 20-(200,400-dinitrophenyl)-5a-
cholestano [5,7-c d] pyrazoline 4–6 was done using Human
cancer cell lines SW480, HeLa, A549, HepG2, HL-60.
SW480, A549, HepG2 and HL-60 cells were grown in RPMI
1640 while as HeLa cells were grown in Dulbecco’s modiﬁed
Eagle’s medium (DMEM). After 24 h incubation at 37 C un-
der a humidiﬁed 5% CO2 to allow cell attachment, the cancer
cells in the wells were, respectively, treated with target com-
pounds at various concentrations for 48 h. The experiment
was done in triplicate and the inhibitory concentration (IC)
values were calculated from a dose response curve. IC50 is
the concentration in ‘lM’ required for 50% inhibition of cell
growth as compared to that of untreated control. The growth
inhibitory effect of compound 4–6 towards the cancer cells was
measured by means of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assay in which the cell viability
was measured with the purple formazan that was metabolized
from MTT mitochondrial dehydrogenase, which is active only
in live cells. The data reported in Table 5 indicates that com-
pound 4–6 showed different levels of anticancer inhibition.
The compound 5 showed minimum IC50 = 15.39 (HL-60),
18.31 (A549), 23.52 (HepG2). While compound 4 showed min-
imum IC50 = 26.53 (HepG2), 27.63 (HL-60), 31.71 (A549).
The compound 6 is not showing effective IC50 values (Table
5). Thus compound 5 can be considered better anticancer
agent [IC50 = 15.39 (HL-60)] among compounds 4–6.4. Conclusion
In summary, the successfully developed, convenient and simple
reaction for the synthesis of steroidal pyrazolines involves the
reaction of steroidal a,b-unsaturated ketones and 2,4-dinitro-
phenylhydrazine in DMSO. The reaction completed in
21–36 h and on completion better yields were obtained. This
strategy offered a very straight forward and efﬁcient method
for access to steroidal pyrazolines. During the antibacterial
screening of newly synthesized steroidal pyrazolines, the com-
pound 6 showed impressive behaviour by being more potent
than reference drug in case of S. epidermidis strain and almost
equally potent in case of C. xerosis strain. Thus, compound 6
was found to be the most active compound in case of antibac-
terial activity. During the antifungal screening the compound 6
was also active by showing moderate to good inhibition on
different fungal strains in comparison with the reference drug.
During anticancer assay compound 5 showed minimum IC50
values against HL60 cell line.
Thus the overall idea of appending the pyrazoline moiety to
steroidal nucleus so as to combine the beneﬁcial effects in a
12 Shamsuzzaman et al.single structure by expecting some biological activities like
antibacterial, antifungal and anticancer activity proved to be
successful. In conclusion, the present study showed that the
synthesized compounds can be used as template for future
development through modiﬁcation and derivatization to de-
sign more potent and selective antimicrobial as well as antican-
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